These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. Kosloski MP; Pisal DS; Mager DE; Balu-Iyer SV J Pharm Sci; 2013 Jul; 102(7):2380-94. PubMed ID: 23620343 [TBL] [Abstract][Full Text] [Related]
5. A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach. Scola MR; Baggesen LM; Nichols TC; Key NS; Gallippi CM Thromb Res; 2012 May; 129 Suppl 2(0 2):S57-61. PubMed ID: 22405050 [TBL] [Abstract][Full Text] [Related]
7. ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia. Scola MR; Nichols TC; Zhu H; Caughey MC; Merricks EP; Raymer RA; Margaritis P; High KA; Gallippi CM Ultrasound Med Biol; 2011 Dec; 37(12):2126-32. PubMed ID: 22033127 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Karpf DM; Kjalke M; Thim L; Agersø H; Merricks EP; Defriess N; Nichols TC; Ezban M Haemophilia; 2011 Sep; 17(5):e963-8. PubMed ID: 21682818 [TBL] [Abstract][Full Text] [Related]
9. Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Nichols TC; Raymer RA; Franck HW; Merricks EP; Bellinger DA; DeFriess N; Margaritis P; Arruda VR; Kay MA; High KA Haemophilia; 2010 May; 16 Suppl 3(Suppl 3):19-23. PubMed ID: 20586797 [TBL] [Abstract][Full Text] [Related]
10. Long-term expression of canine FVIIa in hemophilic dogs. Margaritis P Thromb Res; 2010 Apr; 125 Suppl 1(Suppl 1):S60-2. PubMed ID: 20149416 [TBL] [Abstract][Full Text] [Related]
11. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Sabatino DE; Freguia CF; Toso R; Santos A; Merricks EP; Kazazian HH; Nichols TC; Camire RM; Arruda VR Blood; 2009 Nov; 114(20):4562-5. PubMed ID: 19770361 [TBL] [Abstract][Full Text] [Related]
12. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. Nichols TC; Dillow AM; Franck HW; Merricks EP; Raymer RA; Bellinger DA; Arruda VR; High KA ILAR J; 2009; 50(2):144-67. PubMed ID: 19293459 [TBL] [Abstract][Full Text] [Related]
13. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Chen L; Zhu F; Li J; Lu H; Jiang H; Sarkar R; Arruda VR; Wang J; Zhao J; Pierce GF; Ding Q; Wang X; Wang H; Pipe SW; Liu XQ; Xiao X; Camire RM; Xiao W Mol Ther; 2007 Oct; 15(10):1856-62. PubMed ID: 17653101 [TBL] [Abstract][Full Text] [Related]
14. Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins. Wang Q; Shorten D; Xu X; Shaw GD; Schaub RG; Shea C; Brooks J; Sako D; Wiswall E; Xu J; Szklut P; Patel VS Pharm Res; 2006 Aug; 23(8):1743-9. PubMed ID: 16850270 [TBL] [Abstract][Full Text] [Related]
15. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963 [TBL] [Abstract][Full Text] [Related]
16. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Brennan FR; Shaw L; Wing MG; Robinson C Mol Biotechnol; 2004 May; 27(1):59-74. PubMed ID: 15122047 [TBL] [Abstract][Full Text] [Related]